1. Home
  2. SPRC vs ENTO Comparison

SPRC vs ENTO Comparison

Compare SPRC & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRC
  • ENTO
  • Stock Information
  • Founded
  • SPRC 2004
  • ENTO 2014
  • Country
  • SPRC Israel
  • ENTO United States
  • Employees
  • SPRC N/A
  • ENTO N/A
  • Industry
  • SPRC Biotechnology: Pharmaceutical Preparations
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRC Health Care
  • ENTO Health Care
  • Exchange
  • SPRC Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • SPRC 1.2M
  • ENTO 1.3M
  • IPO Year
  • SPRC N/A
  • ENTO 2016
  • Fundamental
  • Price
  • SPRC $0.31
  • ENTO $0.35
  • Analyst Decision
  • SPRC
  • ENTO
  • Analyst Count
  • SPRC 0
  • ENTO 0
  • Target Price
  • SPRC N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • SPRC 2.8M
  • ENTO 252.0K
  • Earning Date
  • SPRC 09-27-2024
  • ENTO 09-24-2024
  • Dividend Yield
  • SPRC N/A
  • ENTO N/A
  • EPS Growth
  • SPRC N/A
  • ENTO N/A
  • EPS
  • SPRC N/A
  • ENTO N/A
  • Revenue
  • SPRC $2,879,000.00
  • ENTO N/A
  • Revenue This Year
  • SPRC N/A
  • ENTO N/A
  • Revenue Next Year
  • SPRC N/A
  • ENTO N/A
  • P/E Ratio
  • SPRC N/A
  • ENTO N/A
  • Revenue Growth
  • SPRC 113.73
  • ENTO N/A
  • 52 Week Low
  • SPRC $0.28
  • ENTO $0.19
  • 52 Week High
  • SPRC $14.22
  • ENTO $14.51
  • Technical
  • Relative Strength Index (RSI)
  • SPRC 38.57
  • ENTO 36.88
  • Support Level
  • SPRC $0.28
  • ENTO $0.28
  • Resistance Level
  • SPRC $0.32
  • ENTO $0.46
  • Average True Range (ATR)
  • SPRC 0.03
  • ENTO 0.05
  • MACD
  • SPRC 0.00
  • ENTO 0.02
  • Stochastic Oscillator
  • SPRC 20.67
  • ENTO 44.44

About SPRC SciSparc Ltd.

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: